ArticleJournal of health economics and outcomes research2022

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece.

George Gourzoulidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.